Hungary: changes in reimbursement as health budget deficit hits 8% of GDP

25 June 2006

The central budget deficit announced by the Hungarian Prime Minister, Ferenc Gyurcsany, will be 8% of country's Gross Domestic Product as opposed to the 4.7% target in the 2006 budget. The deficit has prompted severe financial restrictions including a cap on pharmaceutical spending, where at least 40.0 billion forint ($181.7 million) has to be saved.

The new Hungarian government is due to reveal details of its health care Action Plan to reduce the drugs budget towards the end of June. It is looking at the new Slovakian and German models and there is speculation about the possible introduction of prescription charges or box charges, regulation on prescribing according to active ingredients, capped patient budgets and widening fixed and therapeutic reimbursement. Some new measures will be introduced on July 1 in order to reduce government subsidies and shift drug costs to manufacturers and the country's citizens.

The Hungarian government will reduce the reimbursement rate for around 1,000 drugs 7.5% from July 1. The measure is still related to the reinstatement of drug prices after the 2004 April cuts. The extra 7.5% reimbursement was part of a compensation plan for the population for the reinstallation of the drugs prices in July 2004 after the April price cut. This unpopular measure means about 2.6 billion forint savings for the National Insurance Fund, the OEP.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight